CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
Minocyclinedrug
Likely dose
Minocycline 3mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00630396
NCT00630396Phase 2Completed
CompareCT.gov

Minocycline to Improve Neurologic Outcome in Stroke (MINOS)

David Hess, MD·interventional·Posted Mar 7, 2008·Updated Jan 13, 2012

In Brief

A Phase 2 clinical trial evaluating Minocycline for Stroke, Acute. Completed, enrolled 60 participants across 2 sites.

Detailed Summary

The primary aim of this study is to find out which of 4 different doses of minocycline are safe and well tolerated so that we will know the optimal dose to test in future patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke, Acute
CountriesUnited States
CollaboratorsNational Institute of Neurological Disorders and Stroke (NINDS), University of Kentucky, Oregon Health and Science University

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 7, 2008
Enrollment StartMay 1, 2008
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 18.3 years ago

Interventions

Minocyclinedrug

Dose level 1 = 3mg/kg intravenous (IV) initial dose, followed by 1.5mg/kg every 12 hours times 5 more doses. Dose level 2 = 4.5mg/kg intravenous (IV) initial dose, followed by 2.25mg/kg every 12 hours times 5 more doses. Dose level 3 = 6 mg/kg intravenous (IV) initial dose, followed by 3 mg/kg every 12 hours times 5 more doses. Dose level 4 = 10 mg/kg intravenous (IV) initial dose, followed by 5 mg/kg every 12 hours times 5 more doses